Jefferies Lowers Kenvue (KVUE) PT to $23, Cites Macroeconomic Headwinds for Consumer Health

Kenvue Inc. (NYSE:KVUE) is one of the best up and coming stocks to buy right now. On October 27, Jefferies analyst Keith Devas lowered the firm’s price target on Kenvue to $23 from $25 and maintained a Buy rating on the shares, as the current macroeconomic challenges are impacting consumer health stocks more than the consumer staples sector. Resultantly, Jefferies lowered its price targets and earnings estimates for the entire consumer health coverage ahead of Q3 2025 reports.

Earlier on October 24, Deutsche Bank analyst Stephen Powers also lowered the price target on Kenvue to $18 from $20 with a Hold rating on the shares.

Jefferies Lowers Kenvue (KVUE) PT to $23, Cites Macroeconomic Headwinds for Consumer Health

In other news, board member and Starboard Value CEO, Jeff Smith, stated in an interview with CNBC’s David Faber that Kenvue is working to maximize shareholder value by exploring alternatives through a collaborative effort between the management and the board.

Kenvue Inc. (NYSE:KVUE) operates as a consumer health company in the US, Europe, the Middle East, Africa, Asia-Pacific, and Latin America. It operates through three segments: Self Care, Skin Health and Beauty, and Essential Health.

While we acknowledge the potential of KVUE to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than KVUE and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.